title: Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma.
abstract: Paxillin is a cytoskeletal protein that was recently identified as a component of focal adhesions and links between F-actin and integrin. In this study, 91 renal tumors--65 conventional renal cell carcinomas (RCCs), 14 papillary RCCs, 6 chromophobe RCCs, 4 collecting duct carcinomas, 2 oncocytomas--were investigated for the immunohistochemical expression of paxillin. In a normal kidney, paxillin was predominantly expressed in the cytoplasm of distal tubules, loops of Henle, collecting ducts, and vascular smooth muscle cells. In all of the chromophobe RCCs and oncocytomas, strong expression of paxillin was observed in the tumor cytoplasm. In contrast to these tumors, conventional RCCs, papillary RCCs, and collecting duct carcinomas showed negative reactions for paxillin except for one case in each subgroup with weak reactivity. An immunoblot analysis confirmed the presence of paxillin in healthy kidney, chromophobe RCC, and oncocytoma. These data suggest that paxillin possibly plays a role in signal transductions as a focal adhesion intervening between tumor cells and the extracellular matrix in renal tumors with collecting duct phenotypes such as chromophobe RCCs and oncocytomas, but not in conventional RCCs. In addition, paxillin may be an available marker in distinguishing chromophobe RCCs from conventional or papillary RCCs.
authors.affiliation: First Department of Pathology, Kochi Medical School, Nankoku City, Japan. nkuroda2001@yahoo.com
authors.forename: N
authors.initials: N
authors.lastname: Kuroda
authors.forename: L
authors.initials: L
authors.lastname: Guo
authors.forename: M
authors.initials: M
authors.lastname: Toi
authors.forename: K
authors.initials: K
authors.lastname: Naruse
authors.forename: E
authors.initials: E
authors.lastname: Miyazaki
authors.forename: Y
authors.initials: Y
authors.lastname: Hayashi
authors.forename: C
authors.initials: C
authors.lastname: Yoshikawa
authors.forename: S
authors.initials: S
authors.lastname: Ashida
authors.forename: T
authors.initials: T
authors.lastname: Shuin
authors.forename: H
authors.initials: H
authors.lastname: Enzan
mesh_terms: D018249:Adenoma, Oxyphilic / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D002451:Cell Compartmentation; D003593:Cytoplasm / Q000737:chemistry; D003598:Cytoskeletal Proteins / Q000378:metabolism*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D051419:Paxillin; D010750:Phosphoproteins / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D003598:Cytoskeletal Proteins; D009363:Neoplasm Proteins; C496061:PXN protein, human; D051419:Paxillin; D010750:Phosphoproteins